2 active not recruiting, 2 completed, 1 recruiting, 1 terminated. 7 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Active not recruiting 2, Completed 2, Recruiting 1, Terminated 1, Unknown 1 |
| Phase 2 | 2 | Completed 1, Unknown 1 |
Follow Non-small Cell Carcinoma: new trials by email Literature Review of Non-small Cell Carcinoma trials Research Report on Non-small Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors TSC-204-A0201, TSC-204-C0702, TSC-200-A0201 - Head and Neck Cancer, Cervical Cancer | Phase 1 | Active not recruiting | TScan Therapeutics, Inc. | 840 | 2024-05-06 | 2025-11-17 |
| Combining ICI With SBRT or HypoFrx-RT for ES NSCLC Stereotactic body radiotherapy, Hypofractionated radiotherapy, Durvalumab - Non-small Cell Lung Cancer, Non-small Cell Carcinoma | Phase 1 / Phase 2 | Unknown | Alexander Chi | 83 | 2023-10-09 | 2023-10-03 |
| Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours DO-2 - Adult Solid Tumor, Advanced Solid Tumor | Phase 1 | Recruiting | DeuterOncology | 55 | 2022-12-20 | 2026-04-03 |
| Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung Cancer Binimetinib, Pembrolizumab - Non-small Cell Carcinoma | Phase 1 | Active not recruiting | University Health Network, Toronto | 40 | 2019-09-20 | 2026-06-23 |
| A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer RGX-104, Ipilimumab, Docetaxel - Endometrial Cancer, Endometrial Cancer Recurrent | Phase 1 | Completed | Inspirna, Inc. | 146 | 2016-11-01 | 2025-03-26 |
| Safety Study of SEA-CD40 in Cancer Patients Intravenous (IV) SEA-CD40, Pembrolizumab, Subcutaneous (SC) SEA-CD40 - Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell | Phase 1 | Terminated | Seagen Inc. | 159 | 2015-02-28 | 2023-05-01 |
| Vaccine Treatment for Advanced Non-Small Cell Lung Cancer Drug: Hyperacute Lung Cancer Cell Vaccine - Non-small Cell Carcinoma, Adenocarcinoma of Lung | Phase 1 / Phase 2 | Completed | NewLink Genetics Corporation | 54 | 2003-11-01 | 2020-05-28 |
Carcinoma, Non-Small-Cell Lung (5) · Lung Neoplasms (3) · Neoplasms (3) · Carcinoma, Squamous Cell (2) · Head and Neck Neoplasms (2) · Melanoma (2) · Adenocarcinoma of Lung (1) · Carcinoma, Large Cell (1) · Endometrial Neoplasms (1) · Hodgkin Disease (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Non-Hodgkin (1)
Neoplasms by Site (6) · Bronchial Neoplasms (5) · Carcinoma, Bronchogenic (5) · Lung Diseases (5) · Respiratory Tract Diseases (5) · Respiratory Tract Neoplasms (5) · Thoracic Neoplasms (5) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Carcinoma (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Genital Diseases (2) · Genital Diseases, Female (2) · Genital Neoplasms, Female (2)
pembrolizumab (3) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Carboplatin (1) · Docetaxel (1) · Gemcitabine (1) · Injections, Subcutaneous (1) · Ipilimumab (1) · Pemetrexed (1) · Radiation Dose Hypofractionation (1) · Radiosurgery (1) · binimetinib (1) · durvalumab (1)
Alexander Chi (1) · DeuterOncology (1) · Inspirna, Inc. (1) · NewLink Genetics Corporation (1) · Seagen Inc. (1) · TScan Therapeutics, Inc. (1) · University Health Network, Toronto (1)
United States (4) · Belgium (1) · Canada (1) · China (1) · France (1) · Netherlands (1)
Alexander Chi, MD (1) · Arun Rajan, M.D. (1) · Dawn Pinchasik, MD (1) · Jaap Verweij, MD (1) · Michael Schmitt, MD, PhD (1) · Natasha Leighl, M.D. (1) · Robert Wasserman, MD (1)